

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

NCT07253285

Status	RECRUITING
Phase	Phase 3
Sponsor	Novo Nordisk A/S
Enrollment	460 participants

Key Eligibility Criteria

Inclusion (15)

- Informed consent of parent(s) or legally acceptable representative (LAR) of participant and child assent, as age-appropriate, obtained before any study related activities. Study related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
- The parent(s) or LAR of the child must sign and date the Informed Consent Form (according to local requirements)
- The child must sign and date the Child Assent Form or provide oral assent (according to local requirements).
- Male or female.
- Aged 8 to less than (<) 18 years at the time of signing the informed consent.

... and 10 more (see full listing online)

Exclusion (14)

- Treatment with any medication prescribed for obesity or weight management within 90 days before screening.
- Previous or planned (during the study period) obesity treatment with surgery or a weight loss device. However, the following are allowed:
 - Liposuction and/or abdominoplasty, if performed > 1 year before screening.
 - Adjustable gastric banding, if the band has been removed > 1 year before screening.
 - Intra-gastric balloon, if the balloon has been removed > 1 year before screening.

... and 9 more (see full listing online)

Locations (119 total)

Neighborhood Healthcare, Escondido, California, United States
Encore Medical Research LLC, Hollywood, Florida, United States
Jacksonville Ctr for Clin Res, Jacksonville, Florida, United States

... and 116 more locations